



(11) **EP 1 457 482 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Claims EN 2**

(51) Int Cl.:

**C07C 229/08** <sup>(2006.01)</sup> **C07C 229/24** <sup>(2006.01)</sup>  
**C07C 229/26** <sup>(2006.01)</sup> **C07C 229/36** <sup>(2006.01)</sup>  
**C07C 323/58** <sup>(2006.01)</sup> **C07B 59/00** <sup>(2006.01)</sup>  
**C12P 21/00** <sup>(2006.01)</sup> **G01N 24/08** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**24.10.2012 Bulletin 2012/43**

(86) International application number:

**PCT/JP2002/013303**

(45) Date of publication and mention of the grant of the patent:

**18.01.2012 Bulletin 2012/03**

(87) International publication number:

**WO 2003/053910 (03.07.2003 Gazette 2003/27)**

(21) Application number: **02793357.1**

(22) Date of filing: **19.12.2002**

(54) **Stable isotope-labeled amino acid, method of integrating the same into target protein, method of NMR structural analysis of protein**

Mit stabilen Isotopen markierte Aminosäure, Verfahren zu deren Einschleusung in ein Zielprotein, Verfahren zur NMR-Strukturanalyse von Protein

Amino acide marqué par isotope stable, technique d'intégration de cet amino acide dans une protéine cible, technique d'analyse structurale par IRM de protéine

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
IE IT LI LU MC NL PT SE SI SK TR**

(30) Priority: **19.12.2001 JP 2001386823**  
**30.01.2002 JP 2002022446**

(43) Date of publication of application:  
**15.09.2004 Bulletin 2004/38**

(73) Proprietor: **Japan Science and Technology Agency**  
**Kawaguchi-shi,**  
**Saitama 332-0012 (JP)**

(72) Inventors:  
• **KAINOSHO, Masatsune**  
**Suginami-ku, Tokyo 167-0033 (JP)**  
• **TERAUCHI, Tsutomu**  
**Hachioji-shi, Tokyo 192-0364 (JP)**

(74) Representative: **Horner, Martin Grenville et al**  
**Marks & Clerk LLP**  
**Aurora**  
**120 Bothwell Street**  
**Glasgow**  
**G2 7JS (GB)**

(56) References cited:  
**EP-A1- 0 299 425 WO-A-94/18339**  
**WO-A-99/11589 JP-A- 2 208 579**  
**JP-A- 5 236 986**

- **WALKER JOEL R. ET AL.:** 'Improved synthesis of (R)-glycine-d-15N' **TETRAHEDRON** vol. 57, no. 31, 30 July 2001, pages 6695 - 6701, XP004275003
- **MAHON MARRITA M. ET AL.:** 'The pyridoxal-5'-phosphate-dependent catalytic antibody 15A9' **FEB LETTERS** vol. 427, no. 1, 1998, pages 74 - 78, XP004259033
- **MOLDES MILAGROS ET AL.:** 'Hydrogen-deuterium exchange in the perfused rat liver metabolizing (3-13C) alanine and 2H20 as detected by multinuclear NMR spectroscopy' **NMR IN BIOMEDICINE** vol. 7, no. 6, 1994, pages 249 - 262, XP002967615

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 457 482 B9**

- OBA MAKOTO ET AL.: 'Synthesis of 13C/D doubly labeled L-leucines' JOURNAL OF ORGANIC CHEMISTRY vol. 66, no. 17, 24 August 2001, pages 5919 - 5922, XP002967616
- SON JONG-KEUN ET AL.: 'Stereochemical mechanism of iodoacetic acid mediated decomposition of L-methionine to L-homoserine lactone' JOURNAL OF THE AMERICAN CHEMICAL SOCIETY vol. 111, no. 4, 1989, pages 1363 - 1367, XP002967617
- OBA MAKOTO ET AL.: 'Synthesis of (3,4-d2) lysine using deuterated pyroglutamate derivative as a chiral template' JAPANESE JOURNAL OF DEUTERIUM SCIENCE vol. 8, no. 1, 1999, pages 11 - 15, XP002967618
- PRABHAKARAN P.C. ET AL.: 'Biosynthesis of blasticidin S from L-alpha-arginine' JOURNAL OF THE AMERICAN CHEMICAL SOCIETY vol. 110, no. 17, 1988, pages 5785 - 5791, XP002967619
- OBA MAKOTO ET AL.: 'Synthesis of L-threo- and L-erythro-(1-13C,2,3-2H2)amino acids' JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY no. 12, 1995, pages 1603 - 1609, XP002967620
- GANI DAVID ET AL.: 'Synthesis of a monocyclic beta-lactam stereospecifically labeled at C-4' JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) no. 11, 1983, pages 2811 - 2814, XP002967621
- OBA MAKOTO ET AL.: 'Stereochemical synthesis of deuterium-labeled amino acids using diketopiperazine or proline derivatives as a chiral template' JOURNAL OF DEUTERIUM SCIENCE vol. 5, no. 1, 1996, pages 35 - 39, XP002967622
- EASTON CHRISTOPHER ET AL.: 'Synthesis of each stereoisomer of (3-2H1)phenylalanine and evaluation of the stereochemical course of the reaction of (R)-phenylalanine with (S)-phenylalanine ammonia-lyase' JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY no. 24, 1994, pages 3545 - 3548, XP002967623
- MOCEK URSULA ET AL.: 'Biosynthesis of the modified peptide antibiotic thiostrepton in streptomyces szureus and streptomyces laurentii' JOURNAL OF THE AMERICAN CHEMICAL SOCIETY vol. 115, no. 18, 1993, pages 7992 - 8001, XP002967624
- KOBAYASHI J. ET AL.: 'Nuclear magnetic resonance study of side-chain conformation of tyrosyl residue in (Met5)-enkephalin' BIOCHIMICA ET BIOPHYSICA ACTA vol. 621, no. 2, 1980, pages 190 - 203, XP002967625
- OBA MAKOTO ET AL.: 'Asymmetric synthesis of L-proline regio- and stereoselectively labeled with deuterium' TETRAHEDRON: ASYMMETRY vol. 10, no. 5, 1999, pages 937 - 945, XP004162517
- TSUTOMU HOSHINO ET AL.: 'Studies on the biosynthesis of violacein. Part II' AGRICULTURAL AND BIOLOGICAL CHEMISTRY vol. 51, no. 10, 1987, pages 2733 - 2741, XP002967626
- THE JAPANESE BIOCHEMICAL SOCIETY, 1991, TOKYO KAGAKU DOJIN article 'Shinsei kagaku jikken koza 1 tanpakushitsu IV', pages 204 - 206, XP002967627

**Description**

**[0001]** Stable isotope-labeled amino acid and method for incorporating the same into target protein, NMR method for the structural analysis of protein.

5

## Background of the Invention

**[0002]** The present invention relates to a stable isotope-labeled amino acid and method for incorporating the same into target protein, and NMR method for the structural analysis of protein.

**[0003]** In the determination of the protein structure by NMR, a sample uniformly labeled with stable isotopes such as  $^{13}\text{C}/^{15}\text{N}$  has so far been used. However, this technique sharply becomes difficult when the molecular weight of the protein exceeds 20,000. There were proposed methods for solving this problem such as a method wherein about 50 to 80 % of hydrogen in the protein is replaced at random with deuterium ( $^2\text{H}$ ) in addition to the labeling with  $^{13}\text{C}/^{15}\text{N}$  to utilize NMR signals of the nucleus of remaining hydrogen ( $^1\text{H}$ ) and a method wherein all the hydrogen atoms except those in methyl group and aromatic ring in the amino acid residue are replaced with deuterium. However, the subject and the utility of those conventional methods are limited because these techniques sacrificed of the accuracy of structural information to determine the structure of high-molecular weight proteins.

15

**[0004]** In WO 99/11589 amino acids labelled in the backbone with  $^{13}\text{C}$ ,  $^{15}\text{N}$ , and  $^2\text{H}$  are described for use in protein structure determination.

20

**[0005]**  $[1-^{13}\text{C}, 2,3-^2\text{H}_2]$  phenylalanine,  $[^2\text{H}_2]$  serine and  $[^2\text{H}_2]$  alanine are described in a paragraph of Analysis of higher-order structure of protein by main chain carbonyl  $^{13}\text{C}$ -NMR of Protein III Higher-order structure in "Shin Seikagaku Jikken Koza (Lectures on New Biochemistry Experiments)" I published by Tokyo Kagaku Dojin on November 15, 1990. However, this technique is employed for the determination of dihedral angle  $\alpha$  of amino acids by a specific multi-labeling method. It has not yet been tried that not only the labeled amino acids but also other amino acids are labeled and these amino acids are incorporated into a target protein to analyze the stereostructure thereof.

25

## Disclosure of the invention

**[0006]** The object of the present invention is to achieve the replacement with deuterium in protein without damaging the NMR sensitivity of the other hydrogen nuclei and also to achieve the rapid analysis of NMR spectra of protein having a molecular weight far higher than that in the prior method and the high-performance determination of the stereostructure.

30

**[0007]** Another object of the present invention is to provide a combination of a stable isotope-labeled amino acid suitably usable for method for NMR structure analysis of a target protein by the NMR spectra determination with a stable isotope-labeled amino acid constituting the target protein.

35

**[0008]** Still another object of the present invention is to provide a method for incorporating a stable isotope-labeled amino acid(s) into a target protein.

**[0009]** A further object of the present invention is to provide an NMR method for analyzing the structure of a protein.

**[0010]** The above-described objects and other objects of the present invention will be apparent from the following description and Examples.

40

**[0011]** The above-described problems can be solved by the present invention. At first, the present invention provides a stable isotope-labeled amino acid which is at least one of amino acids constituting a protein and which has at least one of the following labeling patterns:

(a) hydrogen atoms except at least one hydrogen atom in one or more methylene groups are deuterated,

45

(b) hydrogen atoms in one of prochiral gem-methyl groups are completely deuterated,

(c) hydrogen atoms in prochiral methyl groups are partially deuterated, and

(d) all hydrogen atoms except one of them in a methyl group are deuterated and hydrogen atoms in the aromatic ring are partially deuterated;

and wherein all carbon atoms having remaining hydrogen atoms in the methylene group and/or methyl group are replaced with  $^{13}\text{C}$ ; and all nitrogen atoms are replaced with  $^{15}\text{N}$ .

50

**[0012]** Secondly, the present invention provides a method for incorporating stable isotope-labeled amino acid(s) into a target protein, which is characterized by incorporating the stable isotope-labeled amino acids into a target protein by cell-free protein synthesis system.

55

**[0013]** Thirdly, the present invention provides a method for NMR analysis of the structure of protein by incorporating isotope-labeled amino acid(s) into the target protein and determining NMR spectra to analyze the structure.

## Brief Description of the Drawings

**[0014]**

- 5 Fig. 1 shows the structures of designed deuterides of 20 amino acids constituting protein.  
 Fig. 2 shows a comparative example of  $^1\text{H}$ - $^{13}\text{C}$  HSQC spectra of EPPIb protein (18.2 kDa) containing SSD-glycine incorporated thereinto.  
 Fig. 3 shows a comparative example of HCCT TOCSY spectra of EPP1b protein (18.2 kDa) containing SAD-glycine incorporated thereinto.  
 10 Fig. 4 shows a comparative example of HCCT TOCSY spectra of EPPIb protein (18.2 kDa) containing SAD-glutamine incorporated thereinto.  
 Fig. 5 shows a comparative example of  $^1\text{H}$ - $^{13}\text{C}$  HSQC spectra in  $^1\text{H}$ - $^{13}\text{C}$   $\beta$  region of EPP1b protein (18.2 kDa) containing SAD/PDM-leucine incorporated thereinto.  
 Fig. 6 shows a comparative example of  $^1\text{H}$ - $^{13}\text{C}$  HSQC spectra in  $^1\text{H}$ - $^{13}\text{C}$   $\gamma$  region of EPP1b protein (18.2 kDa) containing SAD/PDM-leucine incorporated thereinto.  
 15 Fig. 7 shows a comparative example of  $^1\text{H}$ - $^{13}\text{C}$  HSQC spectra in  $^1\text{H}$ - $^{13}\text{C}$   $\gamma$  region of EPPIb protein (18.2 kDa) containing SAD/PDM-methionine incorporated thereinto.  
 Fig. 9 shows a comparative example of slice data of H 92 signals.  
 Fig. 10 shows the results of a simulation of the calculation of the structure of lysozyme.  
 20 Fig. 11 shows a combination of stable isotope-labeled amino acids (SAIL amino acids) used for synthesizing calmodulin.  
 Fig. 12 shows  $^1\text{H}$ - $^{13}\text{C}$  CT-HSQC spectra of calmodulin protein synthesized by using the combination of SAIL amino acids shown in Fig. 11.  
 Fig. 13 shows the final 20 structures obtained by the structure calculation with CYANA of calmodulin protein synthesized from the combination of SAIL amino acids shown in Fig. 11.  
 25

## Best Mode for Carrying out the Invention

- 30 **[0015]** The present invention is characterized as described above, and the mode for carrying out the invention will be described below.
- [0016]** It is to be emphasized that the most important point in the NMR analysis of the stable isotope-labeled amino acids and protein containing them in the present invention is as follows: hydrogen at a specified position in a specified steric environment is strictly selected and deuterated unlike a conventional technique wherein the deuterium exchange of amino acid is conducted at random. By this technique, hydrogen atoms unnecessary for the determination of the structure are completely deuterated, while the sensitivity of necessary hydrogen atoms is not lowered at all. As a result, unnecessary signals disappeared, the accuracy of the obtained stereostructure is improved and the time required for the signal analysis and structure determination is remarkably shortened.
- 35 **[0017]** Various techniques can be employed for the deuteration and chemical synthesis of the labeled amino acids in the present invention. For example, they can be chemically synthesized according to a reaction scheme which will be shown in Examples given below.
- [0018]** The stable isotope-labeled amino acid(s) thus prepared is then incorporated into a target protein for the structure analysis of the protein by NMR.
- [0019]** Any one or more of the amino acids constituting protein or all of them can be replaced with stable isotope-labeled amino acid(s) having a pattern capable of making the obtainment of the stereostructure information and NMR spectra analysis most effective. The technique of preparing a protein for this purpose may be any of a technique for synthesizing ordinary high-expression protein with cultured biological cells, a technique for synthesizing peptides and protein by the organic chemistry or enzyme chemistry, or a technique for obtaining a protein by using a cell-free extract. The control of the isotopic dilution and diffusion by the amino acid metabolism is easy in the present invention, while they were not easy and they posed problems in the ordinary technique wherein cultured biological cells were used. It is made possible by the present invention that labeled amino acids, which cannot be easily synthesized in a large amount, can be highly efficiently incorporated into protein. In view of those facts, the method for synthesizing a protein by using the cell-free extract is very excellent and suitable for the purpose of the present invention. However, this fact does not deny the practical value of other techniques.
- 45 **[0020]** Various techniques may be employed for the spectral determination by NMR and also for the structure analysis of protein. It is also possible to specify the changed position in the structure by the ligand bond.
- [0021]** Anyway, the most important characteristic feature of the present invention resides in that amino acids used herein have various deuterium-labeled patterns. The main point of the present invention is that by incorporating those amino acids into protein, advantages which could not be obtained in the prior method can be obtained in the analysis
- 55

of the stereostructure of the protein. It is thus indispensable for understanding the outline of the present invention to clearly define the various deuterium-labeled patterns. The definition of each pattern of the deuteration will be described below.

5 Stereo-selective deuteration (SSD):

**[0022]** Even when one of methylene protons, i. e. gem-methyl groups (for example, two prochiral methyl groups of Val and Leu), of amino acids is completely erased from the spectra by the deuteration, a necessary stereostructure information can be obtained from the steric assignment (pro-R, pro-S) information of the other proton (remaining proton) and the tetrahedrality in the surroundings of carbon atom. In this case, it is preferred to keep carbon atom of methyl group to be erased to simplify the spin system. It is also possible to obtain accurate information of branched amino acids such as Val, Leu and Ile in the signal assignment of a side chain by ordinary magnetization in which the magnetic charge weakens in the course of starting from the main chain till the detection in the side chain.

15 Regio-selective deuteration, RSD:

**[0023]** When the spin system of a side chain of an amino acid is complicated, the spin system can be remarkably simplified by selectively deuterate a specific position to remarkably easily obtain the information of the stereostructure of the protein.

20

Stereo-array deuteration, SAD:

**[0024]** When two or more prochiral centers are present, an extremely large number of isotopomers are produced by the ordinary deuteration to seriously lower the sensitivity and accuracy in the determination of the structure information. In such a case, only single isotopomer can be realized by stereo-selective deuteration while the stereo-chemical inter-relationship between new chiral centers formed by the deuteration is kept. This new labeled pattern will be called "stereo-array deuteration" hereinafter.

25

Proton-density minimization, PDM:

30

**[0025]** Hydrogen atoms in methyl group, aromatic ring, etc. are magnetically equivalent. Therefore, they have protons having Surplus structure information. The proton density in protein can be minimized by deuterating all protons ( $\text{CH}_3 \rightarrow \text{CHD}_2$  or the like), leaving necessary and minimum protons. This technique is called the proton-density minimization.

35

**[0026]** According to the definitions described above, the stable isotope-labeled amino acids practically have the following labeling patterns as described above in the first mode of the present invention:

40

- (a) hydrogen atoms except at least one hydrogen atom of one or more methylene groups are stereo-selectively deuterated ( $\text{CDH}$ ),
- (b) hydrogen atoms in one of prochiral gem-methyl groups are completely deuterated ( $\text{CD}_3$ ),
- (c) hydrogen atoms in prochiral methyl groups are partially deuterated ( $\text{CDH}_2$ ,  $\text{CD}_2\text{H}$ ), and
- (d) all hydrogen atoms except one of them in methyl group are deuterated ( $\text{CD}_2\text{H}$ ) and hydrogen atoms in the aromatic ring are partially deuterated.

45

**[0027]** By combining the deuteration techniques classified as described above, amino acids optimum for obtaining information of stereostructure of protein can be designed. In the deuteration of methylene group and methyl group in the present invention, as described above, it is preferred from the viewpoint of NMR determination technique that all carbon atoms having hydrogen atoms which remain after the main chain and side chain signal assignment are replaced with  $^{13}\text{C}$  and that all nitrogen atoms constituting amino acids are replaced with  $^{15}\text{N}$ . On the other hand, when hydrogen atoms are to be completely removed as  $\text{CD}_3$ , it is advantageous to leave carbon as  $^{12}\text{C}$  so that no spin coupling is contained between  $^{13}\text{C}$ - $^{13}\text{C}$ . The term "assignment" herein indicates the position of the residue, from which the signal is derived, in the amino acid sequence.

50

**[0028]** In the first mode described above, it is preferred that in the stable isotope-labeled amino acids, all amino acids constituting the target protein are used in the form of a combination of stable isotope-labeled amino acids for constituting the target protein and having the following label patterns:

55

- (a) when a methylene group having two hydrogen atoms is present, one of methylene hydrogen atoms is deuterated,
- (b) when prochiral gem-methyl groups are present, all hydrogen atoms in one methyl group are completely deuterated

and hydrogen atoms in the other methyl group are partially deuterated,

(d) when a methyl group other than those stated above is present, all hydrogen atoms except one of them in the methyl group are deuterated or all hydrogen atoms in the methyl group are deuterated,

(e) when the aromatic ring has hydrogen atoms, the hydrogen atoms in the aromatic ring may be partially deuterated,

(f) after the deuteration in above (a), (b) and (d), all carbon atoms of hydrogen atom-containing methylene group and/or methyl group are replaced with  $^{13}\text{C}$ , and

(g) all nitrogen atoms are replaced with  $^{15}\text{N}$ .

**[0029]** Further, when the aromatic ring has hydrogen atoms, these hydrogen atoms are preferably partially deuterated. It is preferred that (f) after the deuteration in above (a), (b) and (d), all carbon atoms in hydrogen atom-containing methylene group and methyl group are converted into  $^{13}\text{C}$ . It is also preferred that carbon atoms constituting carbonyl group and guanidyl group in amino acids are replaced with  $^{13}\text{C}$ . Preferably, all carbon atoms bonded with  $^1\text{H}$  are completely replaced with  $^{13}\text{C}$ .

**[0030]** Fig. 1 shows structures of 20 stable isotope-labeled amino acids designed from the amino acids constituting protein by combining all of these techniques. The target of the patterns shown in Fig. 1 is the application of them to the determination of the stereostructure of protein. Further, various designs are also possible according to the necessary structure information or properties of the target protein.

**[0031]** For the incorporation of stable isotope-labeled amino acids into the target protein in the second mode of the present invention, a preferred method comprises cell-free protein synthesis system by using a combination of the above-described stable isotope-labeled amino acids as the whole amino acids constituting the target protein to prepare the target protein comprising the stable isotope-labeled amino acids.

**[0032]** For analyzing the structure of protein by NMR in the third mode of the present invention, the method for analyzing the NMR structure of a target protein comprises analyzing the structure of a target protein in which all amino acids constituting the target protein are replaced with the above-described stable isotope-labeled amino acids by NMR spectral determination.

**[0033]** The following Examples illustrate the preparation of protein labeled with amino acids having various labeling patterns, and they also prove the fact that NMR spectra of each of them has very excellent characteristics in obtaining the stereostructure.


**[0034]** It is to be noted that the following Examples are only for the concrete understanding of the present invention.

#### Examples

Example 1 Preparation of protein containing SSD-glycine incorporated thereinto and NMR determination:

**[0035]** Steps 1 to 12 illustrate the synthesis of stereo-selectively mono-deuterated (2S)-[1,2- $^{13}\text{C}_2$ ;2- $^{15}\text{N}$ ;2- $^2\text{H}$ ]glycine (hereinafter referred to as SSD-glycine) according to the following scheme 1:

## Scheme 1



&lt;Step 1&gt;

55 **[0036]** Compound (2) (12.55 g, 48.2 mmol, 87 %) was obtained from  $[\text{ul-}^{13}\text{C}_6]$ -glucose (10.06 g, 55.8 mmol) (1) with reference to a method disclosed in a literature (K. P. R. Kartha et al., *Tetrahedron Lett.*, 27, 3415, 1986).

<Step 2, Step 3 and Step 4>

5 [0037] Compound (2) (12.55 g, 48.2 mmol) was converted to compound (3) (22.08 g, 44.3 mmol) by a method disclosed in a literature (Nicolaou et al., J. Am. Chem. Soc., 110, 4673, 1988). 300 ml of 80 % acetic acid was added to compound (3) to obtain a solution. After removing the protecting group at 75°C for 3 hours, the reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The azeotropic process with ethanol was repeated 4 times to obtain compound (4). Then intended compound (5) (12.9 g, 30.2 mmol) was obtained in a yield of 68 % from compound (2) by a method described in a literature (C. Hubschwerlen et al., Synthesis. 962, 1986).

10 <Step 5>

15 [0038] 150 ml of methylene chloride was added to compound (5) (3.66 g, 8.58 mmol) to obtain a solution. Silica gel (73.8 g) and tributyltin deuteride (5.0 g, 7.2 mmol) were added to the solution, and they were stirred for 18 hours. A silica gel column was charged with the reaction mixture. Organotin compounds were eluted with 1 L of methylene chloride and then compound (6a) (3.13 g, 7.29 mmol) was obtained in a yield of 85 %.

<Step 6 and step 7>

20 [0039] Compound (6a) was tosylated at the 5-position with reference to a method described in a literature (Joseph A. Tino et al., J. Med. Chem. 36, 1221, 1993). The obtained compound (7) was dissolved in 83 ml of tetrahydrofuran. 1 M tetrabutylammonium fluoride / tetrahydrofuran solution (13.9 ml, 13.9 mmol) was added to the obtained solution, and they were stirred at room temperature for 15 minutes. The reaction mixture was purified by the silica gel column chromatography with hexane / ethyl acetate = 1/1 to obtain compound (8) (2.73 g, 7.79 mmol, 67 %).

25 <Step 8>

30 [0040] Compound (8) (2.22 g, 6.34 mmol) was dissolved in 110 ml of methylene chloride, and the obtained solution was cooled to 0°C. Dess-Martin reagent (8.05 g, 18.99 mmol) was added to the solution, and they were stirred while the temperature was kept at 0°C. The temperature was elevated to room temperature, and the obtained mixture was stirred for 1.5 hours. 40 ml of saturated sodium hydrogencarbonate solution containing 6 g of sodium thiosulfate and 50 ml of ethyl acetate were added to the reaction mixture, and they were stirred for 5 minutes. After washing with 50 ml of saturated sodium hydrogencarbonate solution twice, with 50 ml of water once and with 50 ml of brine once, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure to obtain compound (9).

35 <Step 9>

40 [0041] A solution of compound (9) in 75 ml of methanol was cooled to 0°C. A solution of sodium borohydride (120 mg, 3.17 mmol) in 50 ml of methanol was added thereto. 2 minutes after, the reaction mixture was taken from the ice bath and stirred for 1.5 hours. 80 ml of acetone was added to the reaction mixture, and they were stirred for 5 minutes. 20 ml of water was added thereto. After the concentration under reduced pressure, 40 ml of ethyl acetate was added to the reaction mixture and they were washed with water (40 ml x 1) and brine (40 ml x 1). The organic layer was dried over sodium sulfate and then concentrated under reduced pressure to obtain compound (10).

45 <Step 10>

[0042] Compound (10) was dissolved in DMF. After the nitrogen replacement, potassium phthalimide (1.76 g, 9.51 mmol) was added thereto. The obtained mixture was stirred at 70°C for 10 hours, concentrated and purified by the silica gel column chromatography with hexane / ethyl acetate = 1/1 to obtain compound (11).

50 <Step 11>

55 [0043] Compound (11) was dissolved in a solvent mixture of 50 ml of acetic acid and 50 ml of 5 N sulfuric acid, and the obtained solution was stirred at 65°C for 1 hour. After cooling to room temperature, KMnO<sub>4</sub> (4.15 g, 26.11 mmol) was added to the reaction mixture and they were stirred at room temperature for 3 hours. Sodium thiosulfate was added to the reaction mixture until the mixture became colorless. Then 20 ml of water was added thereto. After the extraction with methylene chloride (30 ml x 3), the organic phase was washed with water (20 ml x 2), dried over sodium sulfate and concentrated under reduced pressure to obtain compound (12).

<Step 12>

**[0044]** Compound (12) was refluxed in 50 ml of 1 N hydrochloric acid. After cooling, white needle-like crystals thus formed were taken by the filtration. The filtrate was purified with Dowex 50W-X8 to obtain SSD-glycine (13a) (391 mg, 94.95 mmol, 78 %).

<Synthesis of compound (6b)>

**[0045]** By converting compound (5) into compound (6b), SSD-glycine (13b) having a reverse configuration at the 2-position can be synthesized.

**[0046]** Namely, compound (5) (5.0 g, 11.72 mmol) was dissolved in diethyl ether (300 ml), and the obtained solution was cooled to 0°C in argon atmosphere. Magnesium dibromide / diethyl ether complex (17.96 g, 69.54 mmol) was added to the obtained solution, and they were stirred for 5 minutes. Lithium tri-tert-butoxyaluminum deuteride (8.88 g, 34.77 mmol) was added thereto, and they were stirred at 0°C for 4 hours. 30 ml of 1 N hydrochloric acid was added to the reaction mixture at 0°C, and they were stirred for 10 minutes. After the extraction with ethyl acetate (250 ml x 4), the organic layer was washed with brine (100 ml x 1), dried over magnesium sulfate and concentrated under reduced pressure to obtain compound (6b).

<Preparation of labeled protein>

**[0047]** Proline cis-trans isomerase EPP1b (molecular weight: 18 kDa) from *Escherichia coli* was used as the model protein for establishing a process for highly selectively incorporating the above-described SSD-glycine (13a and 13b). In conventional *in vivo* protein preparation method wherein *E. coli* or the like is used, it was difficult for methylene proton of Gly to control the isotopic dilution or diffusion by the action of serine hydroxymethyl transferase (SHMT) which catalyzes the mutual conversion of glycine and serine. The inventors of the present invention have succeeded in the preparation of isotope-labeled EPP1b {the labels being two kinds of SSD-glycine and (2S)- and (3R)-[1,2-<sup>13</sup>C<sub>2</sub>; 1-<sup>15</sup>N; 2-<sup>2</sup>H]-Gly} by an *in vitro* protein synthesizing method with S30 cell-free extract (hereinafter referred to as "cell-free protein synthesis system") while a high stereo-selectivity is kept because the protein-synthesizing function is not lowered even by the addition of a sufficient amount of cycloserine known to be an inhibitor for SHMT.

<NMR determination of labeled protein>

**[0048]** Samples for NMR determination were prepared with SSD-glycine-labeled EPP1b under conditions described in a thesis (E. Kariya et al., *J. Biomol. NMR* 18, 75-76, 2000). The signal assignment of methylene proton of glycine residue was based on the assignment information of main chain NMR signal described in this thesis.


**[0049]** <sup>1</sup>H-<sup>13</sup>C HSQC spectra of EPP1b sample having (2S)- and (3R)-[1,2-<sup>13</sup>C<sub>2</sub>; 1-<sup>15</sup>N; 2-<sup>2</sup>H]-glycine incorporated thereto and that of EPP1b sample having [1,2-<sup>13</sup>C<sub>2</sub>; 1-<sup>15</sup>N]-glycine incorporated thereto are compared with each other in Fig. 2. The following fact is apparent from Fig. 2. In the conventional method wherein a uniformly labeled sample is used, NMR spectra are crowded to make the stereospecific assignment of methylene proton indispensable for the determination of the stereostructure of protein practically impossible. On the other hand, when protein having stereospecifically deuterated SSD-glycine incorporated thereto is tested, the total number of signals in NMR spectra is reduced to a half and increase in the signal cleavage and increase in the line width due to the spin coupling of methylene protons are omitted. Thus, in the spectra, glycine-selective labeling is simplified and all the signals can be separately observed on the two-dimensional NMR. In addition, the assignment of stereospecific signals has already been completed in the step of the preparation of the sample and, therefore, the assignment is unnecessary. The important point is that because the stereochemical assignment has already been completed, only one of the two SSD-glycine-labeled protein samples is necessary.

**[0050]** Namely, according to the technique described, signals unnecessary for the determination of the structure disappeared and the time required for the signal analysis and the structure determination is remarkably shortened.

Example 2 Preparation of protein containing SAD-lysine and NMR determination:

**[0051]** The synthesis of (2S,3R,4R,5S,6R)-[1,2,3,4,5,6-<sup>13</sup>C<sub>6</sub>; 2,6-<sup>15</sup>N<sub>2</sub>; 3,4,5,6-<sup>2</sup>H<sub>4</sub>]lysine (hereinafter referred to as "SAD-lysine) in steps 13 to 16 will be illustrated according to the following scheme 2:

## Scheme 2



<Step 13>

30 [0052] (2S, 3S, 4R)-[1,2,3,4,5- $^{13}\text{C}_5$ ; 2- $^{15}\text{N}$ ; 3,4- $^2\text{H}_2$ ]glutamic acid (hereinafter referred to as SAD-glutamic acid) (14) (25.02 mmol) derived from uniformly  $^{13}\text{C}$ -labeled L-glutamic acid by a method described in a literature (M. Oba, et al., J. Org. Chem. 64, 9275, 1999) was dissolved in 0.2 M solution (200 ml) of pyridine hydrochloride in deuterium oxide. The pH of the obtained solution was adjusted at 5 with pyridine containing pyridoxal phosphate (200 mg) and dithiothreitol (120 mg). Glutamic acid decarboxylase (1000 U, 210 ml) was added to the solution and the obtained mixture was stirred at 37°C for 3 hours while shielding the light. The obtained reaction mixture was concentrated at a temperature of not higher than 30°C under reduced pressure. The residue was purified with SK1B. The labeled aminobutanoic acid thus obtained was dissolved in 50 ml of water. Sodium hydrogencarbonate (2.83 g, 26.66 mmol) and N-ethoxycarbonyl-phthalimide (6.37 g, 29.08 mmol) were added to the obtained solution. The obtained mixture was stirred at room temperature for 1 hour. The reaction solution was adjusted to pH 5 by carefully adding concentrated hydrochloric acid. Crystals thus formed were taken by the filtration. The crystals on the filter paper were washed with cold water and then dried in a vacuum drying vessel to obtain compound (15) (4.43 g, 18.32 mmol, 75 %).

35

40

<Step 14>

45 [0053] Compound (15) was dissolved in methylene chloride (20 ml). Thionyl chloride (11.9 g, 100 mmol) was added to the obtained solution at room temperature. The obtained solution was stirred at room temperature for 1 hour and then at 40°C for 2 hours. The reaction solution was concentrated under reduced pressure. The obtained residue was dissolved in benzene. Tetrakis(triphenyl)phosphine palladium (0.21 g, 5 w/w %) and tributyltin deuteride (3.227 ml, 12 mmol) were added to the obtained solution in argon atmosphere, and they were stirred at room temperature for 5 minutes. The reaction mixture was concentrated and then the product was purified by the silica gel column chromatography with hexane / ethyl acetate = 7/3 to obtain compound (16) (2.101 g, 9.34 mmol, 93 %).

50

<Step 15>

55 [0054] A solution of a labeled diketopiperazine derivative shown in the figure (1.777 g, 4.95 mmol) and compound (16) (1.013 g, 4.5 mmol) in tetrahydrofuran (45 ml) was cooled to -40°C under stirring in argon atmosphere. A solution of potassium tert-butoxide (0.616 g) in tetrahydrofuran (45 ml) was added to the solution. The temperature of the reaction solution was slowly elevated to room temperature. Saturated ammonium chloride was added thereto. After the extraction with ethyl acetate, the organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium

sulfate and concentrated under reduced pressure. The residue was purified by the silica gel column chromatography with hexane / ethyl acetate = 65/35 to obtain compound (17) (1.270 g, 2.72 mmol, 61 %).

<Step 16>

[0055] Compound (17) (1.251 g, 2.68 mmol) was dissolved in ethyl acetate (20 ml). Platinum dioxide (0.023 g, 0.1 mmol) was added to the obtained solution and air in the reaction vessel was replaced with deuterium gas. The reaction mixture was stirred at room temperature for 2 hours while the pressure of deuterium gas was kept at 1 kgf/cm<sup>2</sup>. The catalyst was removed by the filtration and the reaction mixture was concentrated. Concentrated hydrobromic acid was added to the reaction mixture and they were stirred at 140 °C for 48 hours. After the concentration under reduced pressure, the product was ion-exchanged with Dowex 50W-X8 to obtain SAD-lysine (18) (0.360 g, 1.73 mmol, 65 %).

<Preparation of labeled protein>

[0056] SAD-lysine-labeled EPP1b was prepared by adding SAD-lysine by a method described in a thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000).

<Example of NMR determination of labeled protein>

[0057] An NMR sample was assigned according to information of the assignment of main chain NMR signals of the protein described in a thesis under conditions described in the same thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000).


[0058] HCCH TOCSY spectra of EPP1b sample containing SAD-lysine incorporated therein were determined. Fig. 3 shows the comparison of the results with those of protein containing [ $\mu$ -<sup>13</sup>C; <sup>15</sup>N]-lysine obtained by an ordinary method. It is apparent from Fig. 3 that protein containing SAD-lysine is more simplified than the protein obtained by the ordinary method. Because the signals of side chains of long-chain amino acids were highly sensitively observed, NMR signals of the side chain of the long-chain amino acids which could not be utilized so far are now utilizable for obtaining the structure information.

[0059] Namely, by the technique described, signals unnecessary for the structure determination disappeared and the sensitivity of the remaining signals is improved. Accordingly, the rapid, reliable signal analysis of a high-molecular weight protein and the determination of the stereostructure thereof with high accuracy are made possible over the range of the prior techniques.

Example 3

Preparation of protein containing SAD-glutamine and NMR determination thereof:

[0060] The synthesis of (2S,3S,4R)-(1,2,3,4,5-<sup>13</sup>C<sub>5</sub>; 2,5-<sup>13</sup>N<sub>2</sub>; 3,4-<sup>2</sup>H<sub>2</sub>)]glutamine (hereinafter referred to as "SAD-glutamine") in step 17 will be illustrated according to the following scheme 3:



<Step 17>

[0061] Concentrated sulfuric acid (55  $\mu$ l) was added to methanol (1305  $\mu$ l) and they were cooled to -5 to -10°C. The obtained solution was fed into a 2 ml vial containing SAD-glutamic acid (14) (98 mg, 719  $\mu$ mol). The obtained mixture

was stirred at -4°C for 1 hour and then at room temperature for 2 hours. After the completion of the stirring, 156 µl of carbon disulfide was added to the reaction mixture while the temperature was kept at 0 °C. <sup>15</sup>N-labeled ammonia gas was introduced into the vessel for 14 minutes. After leaving them at room temperature for 10 days, methanol was added thereto and crystals thus formed were taken by the filtration. The filtrate was concentrated and then dissolved in distilled water. After the purification with cation exchange resin DOWEX-50, anion exchange resin IRA96SB and anion exchange resin IRA67 in succession, SAD-glutamine (19) (26 mg) was obtained.

<Preparation of labeled protein>

**[0062]** A protein sample containing the above-described SAD-glutamine (19) incorporated therein was prepared by adding methionine sulfoximine and 6-diazo-5-oxonorleucine which inhibit enzymes concerning the conversion of SAD-glutamine and glutamic acid - glutamine to EPP1b protein as the model protein under conditions described in a thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000). Those labeled products could not be prepared by ordinary *in vivo* protein preparation method because conditions required for inhibiting the metabolic change and for producing protein could not be established.

<Example of NMR determination of labeled protein>

**[0063]** An NMR sample was assigned according to information of the assignment of protein main chain NMR signals described in a thesis under conditions described in the same thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000).

**[0064]** HCCH TOCSY spectra of EPP1b sample containing SAD-glutamine incorporated therein were determined. Fig. 4 shows the comparison of the results with those of protein containing [<sup>13</sup>C; <sup>15</sup>N]-glutamine obtained by an ordinary method. It is apparent from Fig. 4 that protein containing SAD-glutamine is more simplified than the protein obtained by the ordinary method. Because the signals of side chains of long-chain amino acids were observed highly sensitively, NMR signals of the side chain of the long-chain amino acids which could not be utilized so far are now utilizable for obtaining the structure information.


**[0065]** Namely, by the technique described, signals unnecessary for the structure determination disappeared and the sensitivity of the remaining signals is improved. Accordingly, the rapid, reliable signal analysis of a high-molecular weight protein and the determination of the stereostructure thereof with high accuracy are made possible over the range of the prior techniques.

Example 4

Preparation of protein containing SAD/PDM-leucine and NMR determination thereof:

**[0066]** The synthesis of (2S,3R,4R)-[1,2,3,4,5-<sup>13</sup>C<sub>5</sub>; 2-<sup>15</sup>N<sub>2</sub>; 3,5,5,5',5',5'-<sup>2</sup>H<sub>6</sub>]leucine (hereinafter referred to as "SAD/PDM-leucine) in steps 18 to 31 will be illustrated according to the following scheme 4:

## Scheme 4



<Step 18>

**[0067]** Thionyl chloride (4.52 g, 38.0 mmol) was added dropwise to a solution (20 ml) of SAD-glutamic acid (14) (2.56 g, 16.5 mmol) in ethanol under cooling with ice. The obtained mixture was stirred at room temperature for 1 hour and then refluxed for 1 hour. The solvent was evaporated.  $\text{H}_2\text{O}$  was added to the residue. The reaction mixture was neutralized with saturated sodium hydrogencarbonate and then stirred at 150 °C under reduced pressure for 1 hour. The organic matter was extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and then the solvent was evaporated to quantitatively obtain compound (20).

## EP 1 457 482 B9

<Step 19>

5 **[0068]** A suspension (17 ml) of lithium tetrahydroborate (0.40 g, 18.2 mmol) in tetrahydrofuran was added dropwise to a solution (17 ml) of compound (20) (2.73 g, 16.5 mmol) in tetrahydrofuran, and they were stirred at room temperature for 25 hours. 20 % acetic acid (20 ml) was added to the reaction mixture, and they were concentrated under reduced pressure. The residue was treated with Dowex 50W-X8 and then concentrated under reduced pressure. The organic matter was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to obtain compound (21) (1.06 g, 8.65 mmol, 52 %).

10 <Step 20>

15 **[0069]** Tert-butyldimethylsilyl chloride (1.44 g, 9.52 mmol) and imidazole (1.36 g, 19.9 mmol) were added to a solution (10 ml) of compound (21) (1.06 g, 8.65 mmol) in DMF, and they were stirred at room temperature for 21 hours. The reaction mixture was concentrated under reduced pressure, and the product was extracted from the residue by the extraction with diethyl ether. The organic layer was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain compound (22) (1.69 g, 7.14 mmol, 83 %).

20 <Step 21>

25 **[0070]** Di-tert-butyl dicarbonate (1.87 g, 8.57 mmol) was added to a solution (15 ml) of compound (22) (1.69 g, 7.14 mmol) in DMF. Then dimethylaminopyridine (0.87 g, 7.14 mmol) was added thereto and they were stirred at room temperature for 22 hours. The reaction mixture was concentrated under reduced pressure, and the product was extracted from the residue with ethyl acetate. The organic layer was washed with an aqueous potassium hydrogensulfate solution and water and then dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was purified by the silica gel chromatography (developer: hexane / ethyl acetate = 85 /15) to obtain compound (23) (1.90 g, 5.64 mmol, 79 %).

30 <Step 22>

35 **[0071]** 3,3-Dimethylpropyleneurea (1.45 ml, 11.8 mmol) was added to 1 M hexamethyldisilazane sodium amide / tetrahydrofuran solution (11.8 ml, 11.8 mmol), and they were stirred at 0°C for 10 minutes. The reaction solution was cooled to -78°C. A solution (10 ml) of compound (23) (1.90 g, 5.64 mmol) in tetrahydrofuran was added thereto and they were stirred at that temperature for 30 minutes. A solution (10 ml) of phenylselenenyl chloride (1.19 g, 6.20 mmol) in tetrahydrofuran was added to the reaction mixture, and they were stirred at -78°C for 2 hours. Deuterated methyl iodide (0.90 g, 6.20 mmol) was added to the reaction mixture at that temperature. Then the temperature was elevated to room temperature. Ether was added to the reaction mixture. The organic layer was washed with water and saturated aqueous sodium chloride solution and then dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 94 /6) to obtain compound (24) (1.52 g, 3.06 mmol, 54 %).

40 <Step 23>

45 **[0072]** A solution of compound (24) (1.52 g, 3.06 mmol) in tetrahydrofuran (12 ml) was cooled to 0°C, and 30 % aqueous hydrogen peroxide solution (3.47 g, 30.6 mmol) was added dropwise thereto. The temperature was elevated to room temperature. After stirring for one hour, the disappearance of the starting material was confirmed by TLC. After the extraction from the reaction mixture with ether, the organic layer was washed with saturated aqueous sodium carbonate solution and dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 85:15) to obtain compound (25) (0.806 g, 2.36 mmol, 77 %).

50 <Step 24>

55 **[0073]** Platinum dioxide (0.04 g, 5 wt. %) was added to a solution (25 ml) of compound (25) (0.806 g, 2.36 mmol) in methanol, and they were stirred in hydrogen atmosphere for 1 hour. The catalyst was taken by the filtration, and the filtrate was concentrated under reduced pressure to quantitatively obtain compound (26).

<Step 25>

5 **[0074]** p-Toluenesulfonic acid (0.04 g, 0.236 mmol, 10 mol %) was added to a solution (25 ml) of compound (26) (0.81 g, 2.36 mmol) in methanol and they were stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure. After the extraction with ethyl acetate, the extract was washed with saturated aqueous sodium hydrogencarbonate solution. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to obtain compound (27) (0.426 g, 1.78 mmol, 75 %).

10 <Step 26>

15 **[0075]** A mixture of sodium periodate (3.81 g, 17.8 mmol), ruthenium chloride monohydrate (0.11 g) and H<sub>2</sub>O (12 ml) was added to a solution (10 ml) of compound (27) (0.426 g, 1.78 mmol) in acetone, and they were stirred at 0°C for 1 hour. The temperature was elevated to room temperature, and the reaction mixture was stirred for additional 1 hour. The organic layer was separated. Isopropanol (10 ml) was added thereto and they were stirred for 1 hour. The insoluble matter was separated by the filtration. The filtrate was concentrated under reduced pressure and the residue was subjected to the extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate and the solvent was evaporated to quantitatively obtain compound (28).

20 <Step 27>

25 **[0076]** A mixture of N,N-dimethylformamide dineopentylacetal (0.74 g, 3.21 mmol) and tert-butanol (0.40 g, 5.34 mmol) was added to a solution (10 ml) of compound (28) (0.45 g, 1.78 mmol) in benzene under reflux, and they were refluxed for additional 30 minutes. The reaction solution was cooled to room temperature. Ethyl acetate was added thereto. The organic layer was washed with water, saturated aqueous sodium hydrogencarbonate solution and saturated aqueous sodium chloride solution and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 80:20) to obtain compound (29) (0.271 g, 0.88 mmol, 49 %).

30 <Step 28>

35 **[0077]** A solution of compound (29) (0.271 g, 0.88 mmol) in tetrahydrofuran (10 ml) was cooled to 0°C. 1 M aqueous LiOH solution (1.05 ml) was added dropwise to the solution. The temperature of the reaction mixture was elevated to room temperature. After stirring for 30 minutes, the disappearance of the starting material was confirmed by TLC. The product was extracted with saturated aqueous sodium hydrogencarbonate solution and then washed with ethyl acetate. pH of the aqueous layer was adjusted to 3 to 4 with citric acid. The organic product was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then the solvent was evaporated to quantitatively obtain compound (30).

40 <Step 29>

45 **[0078]** A solution (10 ml) of compound (30) (0.287 g, 0.88 mmol) in tetrahydrofuran was cooled to -40°C in argon gas stream. Triethylamine (0.12 g, 1.14 mmol) and isobutyl chloroformate (0.15 g, 1.05 mmol) were added to the solution, and they were stirred for 1 hour. Triethylamine hydrochloride thus precipitated was removed by the filtration in argon stream. The filtrate was cooled to 0°C and a mixture of sodium boron deuteride (0.11 g, 2.63 mmol), tetrahydrofuran (8 ml) and deuterium oxide (6 ml) was added thereto. The obtained mixture was stirred for 1.5 hours. The reaction mixture was diluted with ethyl acetate and then washed with saturated aqueous sodium chloride solution, 10 % aqueous citric acid solution and saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 75:25) to obtain compound (31) (0.168 g, 0.53 mmol, 61 %).

50 <Step 30>

55 **[0079]** Iodine (0.30 g, 1.17 mmol) was added to a suspension (5 ml) of triphenylphosphine (polystyrene-supported 3 mmol) P/g resin, 0.39 g, 1.17 mmol) in dichloromethane, and they were stirred at room temperature for 10 minutes. Then imidazole (0.08 g, 1.17 mmol) was added to the obtained mixture, and they were stirred at room temperature for 10 minutes. A solution (15 ml) of compound (31) (0.168 g, 0.533 mmol) in dichloromethane was added to the reaction mixture, and they were refluxed for 2 hours. The insoluble matter was removed by the filtration and the filtrate was concentrated under reduced pressure. The product was extracted from the residue with ether and then washed with

saturated sodium thiosulfate solution. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain compound (32) (0.199 g, 0.468 mmol, 88 %).

<Step 31>

5  
[0080] Tributyltin hydride (0.21 g, 0.70 mmol) and azobisisobutyronitrile (AIBN) (7.7 mg) were added to a solution (10 ml) of compound (32) (0.199 g, 0.468 mmol) in benzene, and they were stirred for 1 hour. The solvent was evaporated. 1 M hydrochloric acid (15 ml) was added to the residue, and they were refluxed at 130°C for 1 hour. The aqueous layer was washed with chloroform and then concentrated under reduced pressure. After the ion exchange with Dowex 50W-X8, SAD/PDM-leucine (33) (0.0486 g, 0.34 mmol, 73 %) was obtained.

<Preparation of labeled protein>

15  
[0081] A protein sample containing the above-described SAD/PDM-leucine incorporated therein was prepared by adding SAD/PDM-leucine to EPPIb protein as the model protein under conditions described in a thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000).

<Example of NMR determination of labeled protein>

20  
[0082] An NMR sample was assigned according to information of the assignment of protein main chain NMR signals described in a thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000) under conditions described in the same thesis.

[0083]  $^1\text{H}$ - $^{13}\text{C}$ CT-HSQC of EPPIb sample containing SAD/PDM-leucine incorporated therein was determined. Figs. 5 and 6 show the comparison of the results with those of protein containing [ $^{13}\text{C}$ ;  $^{15}\text{N}$ ]-leucine obtained by an ordinary method. It is apparent from Figs. 5 and 6 that signals of protein containing SAD/PDM-leucine is more simplified than those of the protein obtained by the ordinary method. It is to be noted that one of methyl groups in leucine was completely deuterated and carbon atom was kept as nuclear spin-free  $^{12}\text{C}$ , while in the other methyl group, two of the three hydrogen atoms are deuterated and the remaining hydrogen atom, which was the minimum necessary hydrogen atom, was kept for obtaining the structure. The central carbon atom is replaced with  $^{13}\text{C}$  for the NMR determination and assignment. The line width is reduced as the proton density is lowered to almost completely compensate for the reduction in number of protons in the deuteration. In the complicated measurement method for the actual structure determination, the determination sensitivity is expected to be rather remarkably improved as compared with that of ordinary methods.

30  
[0084] Thus, when SAD/PDM-amino acids are used, all carbon atoms having proton are only  $^{13}\text{C}$ - $^1\text{H}$ . Thus, it is made possible to obtain labeled protein samples indispensable for the development of new NMR techniques such as the determination and analysis of the relaxation time and the application of the residual dipole interaction constant to the structure determination.

Example 5 Preparation of protein containing SAD/PDM-methionine incorporated therein and NMR determination:


40  
[0085] Steps 32 to 38 illustrate the synthesis of (2S, 3R, 4R)-[1,2,3,4,6- $^{13}\text{C}_5$ ;2- $^{15}\text{N}$ ;3,4,6,6- $^2\text{H}_4$ ]methionine (hereinafter referred to as SAD/PDM-methionine) according to the following scheme 5:

45

50

55

## Scheme 5



<Steps 32 and 33>

30  
35  
40  
[0086] (2S,3R)-[1,2,3,4-<sup>13</sup>C<sub>4</sub>;2-<sup>15</sup>N;3-<sup>2</sup>H] aspartic acid (34) was converted into compound (35) with reference to a method disclosed in a literature (K. Ramalingam et al., J. Org. Chem. 53, 1900-1903, 1988). Compound (35) (2.82 g, 10 mmol) was dissolved in dichloromethane (10.0 ml). The obtained solution was added dropwise to a solution of Dess-Martinperiodinane (4.84 g, 11.4 mmol) in methylene chloride (30.0 ml) during 20 minutes. After stirring for 1 hour, diethyl ether (50 ml) was added to the obtained mixture and then a mixture of saturated sodium hydrogencarbonate (50.0 ml) and sodium thiosulfate (15.0 g) was added thereto, and they were stirred for 10 minutes. The organic layer was washed with saturated sodium hydrogencarbonate (50.0 ml) and water (50.0 ml) and then dried over magnesium sulfate. The solvent was evaporated, and the obtained crude product was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 1/1) to quantitatively obtain compound (36).

<Step 34>

45  
50  
55  
[0087] A mixture of ethanol (60.6 ml, 2.78 g) and tetrahydrofuran (16.0 ml) and then a solution of (s)-(-)-1,1'-bi-2-naphthol (60.6 mmol, 17.34 g) in tetrahydrofuran (90.0 ml) were slowly added to a mixture of lithium aluminum hydride (60.0 mmol, 2.28 g) and tetrahydrofuran (4.0 ml) with a syringe under stirring in nitrogen atmosphere. The obtained mixture was stirred at room temperature for 30 minutes. The reaction mixture was cooled to -100°C. A solution of compound (36) (1.67 g, 6.00 mmol) in tetrahydrofuran (11.0 ml) was slowly added to the reaction mixture with a syringe, and they were stirred at that temperature for 3 hours. Then the reaction mixture was stirred at -78°C for 10 hours. 0.5 N hydrochloric acid (1.0 ml) was added thereto, and they were stirred for 15 minutes. The reaction mixture was filtered through Hyflo Super Cel. The organic layer was dried over magnesium sulfate, and the solvent was evaporated. Hexane was added to the obtained crude product. Excess naphthol was removed by the crystallization. The product was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 1:1) to obtain compound (37). (0.315 g, 1.12 mmol, 19 %)

<Step 35>

[0088] Compound (37) (0.315 g, 1.12 mmol) was dissolved in methylene chloride (15.0 ml). Triethylamine (0.125 g, 1.23 mmol) was added to the obtained solution in nitrogen stream at 0°C. Then methanesulfonyl chloride (0.141 g, 1.23

## EP 1 457 482 B9

mmol) was added to the mixture and they were stirred for 1 hour. Water (10.0 ml) was added thereto and they were stirred for 15 minutes. The organic layer was washed with 0.5 N hydrogen chloride (30 ml x 2), water (30 ml x 2), saturated sodium hydrogencarbonate (30 ml x 2) and saturated aqueous sodium chloride solution (30 ml x 2) and then dried over magnesium sulfate. The solvent was evaporated. The obtained crude product was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 1/1) to obtain compound (38) (0.360 g, 1.10 mmol, 98 %).

<Step 36>

**[0089]** Water (20 ml), potassium O-t-butyl dithiocarbonate (0.225 g, 1.21 g) and Aliquat 336 (33.0 mg, 37.0  $\mu$ l) were added to compound (38) (0.360 g, 1.10 mmol), and they were strongly stirred at room temperature for 30 minutes. Then the mixture was stirred at 45 to 50°C for 10 minutes. The temperature was elevated to a range of 75 to 80°C during at least 10 minutes and then the mixture was stirred for 20 minutes. After the aqueous layer became transparent and yellow oily product was formed, petroleum ether (20.0 ml) was added to the reaction mixture. The organic layer was washed with water (30.0 ml x 2) and then dried over magnesium sulfate. The obtained crude product was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 1/1) to obtain compound (39). (0.101 g, 0.340 mmol, 31 %).

<Step 37>

**[0090]** Compound (39) (0.101 g, 0.340 mmol) was dissolved in tetrahydrofuran (15.0 ml) in nitrogen stream. 1.6 M n-butyl lithium (0.233 ml) was added to the obtained solution at -78°C and they were stirred for 15 minutes.  $^{13}\text{CD}_2\text{HI}$  (54.2 mg, 0.374 mmol) was added to the obtained mixture, and they were stirred for 90 minutes. Saturated ammonium chloride solution (1.00 ml) was added to the reaction mixture and they were stirred for 5 minutes. The temperature was elevated to room temperature. After evaporating THF, ethyl acetate (30.0 ml) was added to the residue. The organic layer was washed with water (30.0 ml) and saturated aqueous sodium chloride solution (30.0 ml) and then dried over magnesium sulfate. The solvent was evaporated, and the obtained crude product was purified by the silica gel column chromatography (developer: hexane / ethyl acetate = 1/1) to obtain compound (40). (99.3 mg, 0.317 mmol, 93 %).

<Step 38>

**[0091]** 1 N hydrochloric acid (15 ml) was added to compound (40) (99.3 mg, 0.317 mmol), and they were refluxed at 110°C for 3 hours. Water was evaporated. The obtained hydrochloride was dissolved in a small amount of water and then purified with ion exchange resin Dowex 50W-X8 to almost quantitatively obtain SAD/PDM-methionine (41) (50.1 mg, 0.320 mg, >99 %).

<Preparation of labeled protein>

**[0092]** A protein sample containing the above-described SAD/PDM-methionine incorporated thereinto was prepared by adding SAD/PDM-methionine to EPP1b protein as the model protein under conditions described in a thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000).

<Example of NMR determination of labeled protein>

**[0093]** An NMR sample was assigned according to information of the assignment of protein main chain NMR signals described in a thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000) under conditions described in the same thesis.

**[0094]**  $^1\text{H}$ - $^{13}\text{C}$  CT-HSQC of EPP1b sample containing SAD/PDM-methionine incorporated thereinto was determined. Fig. 7 shows the comparison of the results with those of protein containing [ $\mu$ - $^{13}\text{C}$ ;  $^{15}\text{N}$ ]-methionine obtained by an ordinary method. It is apparent from Fig. 7 that protein containing SAD/PDM-methionine is more simplified than the protein obtained by the ordinary method. Because the signals of side chains of long-chain amino acids could be observed highly sensitively, NMR signals of the side chain of the long-chain amino acids which could not be utilized so far are now utilizable for obtaining the structure information.

**[0095]** Namely, by the technique described, signals unnecessary for the structure determination disappeared and the sensitivity of the remaining signals is improved. Accordingly, the rapid, reliable signal analysis of a high-molecular weight protein and the determination of the stereostructure thereof with high accuracy are made possible over the range of the prior techniques. Example 6 Preparation of protein containing aromatic amino acids labeled with SSD at the  $\beta$ -position and NMR determination:

## EP 1 457 482 B9

Synthesis of (2S,3R) and (2S, 3S)-[3,2',3',4',5',6'-<sup>2</sup>H<sub>6</sub>; 1,3-<sup>13</sup>C<sub>2</sub>;2-<sup>15</sup>N]-phenylalanine, tyrosine, tryptophan and histidine:

**[0096]** They were synthesized with reference to a method described in a literature (Makoto Oba et al., J. Chem. Soc., Perkin Trans. 1, 1995, 1603).

<Preparation of labeled protein>

**[0097]** A protein sample containing the above-described stereo-selectively deuterium-labeled aromatic acid was prepared by using EPP1b protein as the model protein under conditions described in a thesis (E. Karia et al., J. Biomol. NMR 18, 75-76, 2000).

<Example of NMR determination of labeled protein>

**[0098]** An NMR sample was assigned according to information of the assignment of protein main chain NMR signals described in a thesis (E. Kariya et al., J. Biomol. NMR 18, 75-76, 2000) under conditions described in the same thesis.

**[0099]** <sup>1</sup>H-<sup>13</sup>C HSQC of EPP1b sample containing labeled aromatic amino acids incorporated thereinto was determined. The comparison of the results with those obtained by an ordinary method was made. It is apparent that NMR spectra of protein containing SSD-labeled amino acids are simplified while NMR spectra of protein obtained by the ordinary method are not simple. The assignment of stereospecific signals without error is also possible.

**[0100]** Slice data of His 92 signals are shown in Fig. 9. As shown in Fig. 9, the signal strength of SSD-labeled histidine is about 7 times as high as that of non-deuterated histidine residue because the former is free from the CH, HH dipole interaction.

**[0101]** Namely, by the technique described, signals unnecessary for the structure determination disappeared and the sensitivity of the remaining signals is improved. Accordingly, the rapid, reliable signal analysis of a high molecular weight protein and the determination of the stereostructure with high accuracy are made possible over the range of the prior techniques.

Example 7 Preparation of protein comprising only stable isotope-labeled amino acids (hereinafter referred to as SAIL amino acids), NMR determination and structure analysis:

**[0102]** SAIL amino acids other than those synthesized in the above-described Examples, i. e. SAIL alanine, SAIL valine, SAIL isoleucine, SAIL serine, SAIL proline and SAIL arginine, were synthesized by methods described below.

Synthesis of SAIL alanine:

**[0103]** This compound was synthesized by the Schiff base alkylation of methyl ester of [1,2-<sup>13</sup>C<sub>2</sub>;2-<sup>15</sup>N]glycine with benzophenimine. The structural formula of synthesized SAIL alanine is shown in Fig. 1.

Synthesis of SAIL-valine:

**[0104]** SAIL valine was synthesized by partially changing a method described in a literature (Jack E. Baldwin et al., Tetrahedron, 51, 4089-4100 (1995)) so as to obtain the intended labeled pattern (scheme 6). Namely, [1,2,3,4-<sup>13</sup>C<sub>4</sub>; 2-<sup>15</sup>N]aspartic acid was used as the substrate, [<sup>2</sup>H<sub>3</sub>]methyl iodide was used as the methylating agent in step 39 and NaBD<sub>4</sub>/MeOD was used for realizing the reduction conditions in Step 40.




Synthesis of SAIL arginine:

[0106] SAIL arginine was synthesized according to scheme 7. Steps 41 to 43 will be illustrated in detail below.


5

## Scheme 7


10



15



20



25

30



35

40 <Step 41>

[0107] Compound (15) (2.41 g, 10 mmol) obtained in step 13 was dissolved in methylene chloride (20 ml). Thionyl chloride (11.9 g, 100 mmol) was added to the obtained solution at room temperature. The obtained solution was stirred at room temperature for 1 hour and then at 40°C for 2 hours. The reaction solution was concentrated under reduced pressure. The obtained residue was dissolved in benzene. Tetrakis(triphenylphosphine) palladium (0.21 g, 5 w/w %) and tributyltin deuteride (3.227 ml, 12 mmol) were added thereto in argon atmosphere and they were stirred at room temperature for 5 minutes. The reaction mixture was concentrated. The product was purified by the silica gel column chromatography with hexane / ethyl acetate = 7/3 to obtain compound (42) (2.101 g, 9.34 mmol, 93 %).

45

50 <Step 42>

[0108] (2R)-[2-<sup>15</sup>N]-Phenylglycine (0.44 g, 3.2 mmol) was added to a solution (32 ml) of compound 42 (0.721 g, 3.2 mmol) in methylene chloride, and they were stirred at room temperature in nitrogen atmosphere for 1 hour. [<sup>13</sup>C]-sodium cyanide (0.32 g, 6.4 mmol) and acetic acid (0.387 ml, 6.4 mmol) were successively added to the reaction mixture, and they were stirred at room temperature for 24 hours. 6 M hydrochloric acid (10 ml) was added to the reaction mixture. After the extraction with chloroform the organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by the flash silica gel column chromatography with hexane / ethyl acetate to obtain compound 43 (0.7624 g, 2.044 mmol, 64 %).

55

<Step 43>

5 **[0109]** Compound 43 (0.7624 g, 2.044 mmol) obtained in step 42 was dissolved in a solution of methanol / chloroform = 1/2 and the obtained solution was cooled to 0C°. Palladium acetate (1.55 g, 3.17 mmol) was added thereto and they were stirred for 5 minutes. 0.2 M phosphate buffer (50 ml) was added to the reaction solution and they were stirred at 0C° for 40 minutes. Crystals thus formed were taken by the filtration, and the filtrate was subjected to the extraction with chloroform. The chloroform layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. Concentrated hydrochloric acid (50 ml) was added to the residue and they were stirred in an oil bath at 140C° for 5 hours. The reaction solution was concentrated and then ion-exchanged with Dowex 50W-X8 to obtain ornithine (0.583 g). Ornithine thus obtained was dissolved in water (3 ml). Basic copper carbonate (1.62 g, 7.32 mmol) was added to the obtained solution, and they were stirred at 80C° for 24 hours. Insoluble crystals were filtered out, and the filtrate was concentrated by the freeze-drying. The obtained solid was dissolved in water (1.8 ml), and the obtained solution was cooled to 0C°. O-methylisourea hydrochloride (0.246 g, 2.116 mmol) and then 7.4 % aqueous sodium hydroxide solution (1.15 ml, 2.116 mmol) were added to the solution. The temperature of the obtained mixture was elevated to room temperature, and the mixture was stirred for 5 days. The reaction solution was purified with Dowex 50W-X8. Hydrochloric acid was added to arginine thus obtained to adjust pH thereof to 6. After freeze-drying, arginine hydrochloride (0.394 g, 1.765 mmol) was obtained.

<Step 44>

20 Synthesis of (2R)-[2-<sup>15</sup>N]phenylglycinol:

25 **[0110]** A magnetic stirrer,  $\alpha$ -bromophenylacetic acid (4.3 g, 20 mmol) and methanol (20 ml) were fed into a 50 ml autoclave tube, and they were cooled with an ice bath. Ammonia gas was introduced therein until the saturation, the tube was tightly sealed and the temperature was elevated to room temperature. After stirring for 24 hours, crystals formed in the reaction system were taken by the filtration and then dried to obtain (2SR)-[2-<sup>15</sup>N]phenylglycine (2.733 g, 17.98 mmol). (2SR)-[2-<sup>15</sup>N]Phenylglycine thus obtained was converted into (2R)-[2-<sup>16</sup>N]phenylglycine by a method described in a literature (T. Shiraiwa et al., Bull. Chem. Soc. Jpn., 64, 191-195, 1991). The yield was 1.90 g (12.498 mmol). Obtained (2R)-[2-<sup>15</sup>N]phenylglycine was converted to (2R)-[2-<sup>15</sup>N]phenylglycinol by a method described in a literature (Ernesto Nicols et al., J. Org. Chem., 58, 766-770, 1993). The yield was (10.125 mmol).

Synthesis of SAIL isoleucine:

35 **[0111]** SAIL Isoleucine was synthesized according to the following scheme 8 and scheme 9 with reference to literatures shown below:

40


45

50

55





Scheme 8

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55



Scheme 9

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55



overall 7% fumaric acid

Diastereomer	Yield(%)
S	83
R	7

## EP 1 457 482 B9

<Step 45, Step 46>

**[0112]** [1,2,3,4-<sup>13</sup>C<sub>4</sub>; 1,1,4,4-<sup>2</sup>H<sub>4</sub>]2,3-butanediol was synthesized from a <sup>13</sup>C uniformly labeled tartaric acid derivative by a method described in a literature (V. Schurig et al., J. Org. Chem., 45, 538-541, 1980).

5

<Steps 47 to 51>

**[0113]** Butanediol obtained in step 46 was converted into isobutyric acid by a method described in a literature (Richard K. Hill et al., J. Am. Chem. Soc., 102, 7344-7348, 1980).

10

<Steps 51 to 54>

**[0114]** Isobutyric acid obtained in Step 51 was converted into SAIL isoleucine by a method described in a literature (Nicholas M. Kelly et al., Tetrahedron Let., 37, 1517-1520, 1996).

15

Synthesis of SAIL threonine:

**[0115]** SAIL threonine was synthesized according to scheme 10 with reference to literatures shown below:

20

25

30

35


40

45

50

55

## Scheme 10

\* =  $^{13}\text{C}$  or  $^{15}\text{N}$ 

&lt;Step 55&gt;

[0116] Compound (8) (794 g, 2.21 mmol) was converted to compound (51) (500 mg, 2.26 mmol) by a method described in a literature (Y. Ueno et al., Chem. Lett. 795 (1983)).

&lt;Step 56&gt;

[0117] Compound (51) (500 mg, 2.26 mmol) was dissolved in 30 ml of methine chloride. The temperature was lowered to  $0^{\circ}\text{C}$ . Dess-Martin reagent (1.90 g, 4.49 mmol) was added to the solution, and they were stirred while the temperature was kept at  $0^{\circ}\text{C}$ . The temperature was elevated to room temperature, and the reaction mixture was stirred for 1.5 hours. 60 ml of saturated sodium hydrogencarbonate containing 12 g of sodium thiosulfate dissolved therein and 50 ml of ethyl acetate were added to the reaction mixture, and they were stirred for 5 minutes. After washing with 50 ml of saturated sodium hydrogencarbonate solution twice, with 50 ml of water once and with 50 ml of brine once, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure to obtain compound (52).

<Step 57>

5 **[0118]** Compound (52) was dissolved in 20 ml of methanol. The obtained solution was cooled to 0C°. A solution of sodium borohydride (70 mg, 1.75 mmol) in 10 ml of methanol was added thereto. 2 minutes after, the obtained mixture was taken out of the ice bath and stirred for 1.5 hours. 10 ml of acetone was added thereto and they were stirred for 5 minutes. 20 ml of water was added to the reaction mixture. After the concentration under reduced pressure, 40 ml of ethyl acetate was added thereto. The reaction mixture was washed with water (40 ml x 1) and brine (40 ml x 1). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain compound (53).

10 <Step 58>

15 **[0119]** Compound (53) was dissolved in methylene chloride. After nitrogen replacement, dimethylaminopyridine (500 mg, 4.03 mmol) and trifluoromethanesulfonyl chloride (500 µl, 4.68 mmol) were added to the reaction mixture, and they were stirred at 0C° for 1 hour. 30 ml of ethyl acetate was added thereto and the mixture was washed with water (20 ml x 2) and brine (20 ml x 1). The organic layer was dried over sodium sulfate and then concentrated under reduced pressure to obtain compound (54).

<Step 59>

20 **[0120]** Compound (54) was dissolved in 80 ml of toluene. After nitrogen replacement, potassium phthalimide (1.40 g, 7.68 mmol) and 18-crown-6 (150 mg, 0.56 mmol) were added to the solution. The obtained mixture was stirred at 130C° for 3 days. 100 ml of ethyl acetate was added thereto and the obtained mixture was washed with water (50 ml x 2) and brine (50 ml x 1). The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The reaction mixture was purified by the silica gel column chromatography with hexane / ethyl acetate - 1/1 to obtain compound  
25 (55) (421 mg, 1.36 mmol, 60 %).

<Step 60>

30 **[0121]** Compound (55) (389 mg, 1.25 mmol) was converted to compound (56) by a method described in a literature (Frieder W. Lichtenthaler, et al., Synthesis. 790, 1988).

<Step 61>

35 **[0122]** Compound (56) (309 mg, 1.21 mmol) was refluxed with 50 ml of 1 N hydrochloric acid for 12 hours. After cooling, white needle-like crystals thus formed were taken by the filtration. The filtrate was purified with Dowex 50W-X8 to obtain threonine (57) (50 mg, 0.400 mmol).

Synthesis of SAIL serine:


40 **[0123]** [1,2,3-<sup>13</sup>C<sub>3</sub>; 2-<sup>15</sup>N]serine was converted to an aldehyde (58) by a method described in a literature (Mark A. Blaskovich et al., J. Org. Chem., 63, 3631-3646, 1998). This product was asymmetrically reduced with (S)-BINAL-D according to scheme 11 and then hydrolyzed to convert it into SAIL serine (60). The structure of SAIL serine thus synthesized is shown in Fig. 1.

45

50

55

## Scheme 11



<Step 62>

[0124]  $\text{LiAlD}_4$  (57.587 mol, 57.587 ml), EtOD (58.162 mmol, 2.738 g, 419 g) in THF (29 ml) and (S)-(-)-binaphthal (58.738 mmol, 16.819 g) dissolved in THF (80 ml) were successively fed into a reactor. After stirring the mixture at room temperature in argon stream for 30 minutes, the temperature was lowered to  $-100^\circ\text{C}$ . A solution of compound (58) (3.728 g, 12.797 mmol) in THF (13 ml) was added to the reaction mixture and they were stirred for 3 hours and then at  $-78^\circ\text{C}$  for 18 hours. After the after-treatment with 0.5 N HCl (200 ml) followed by filtration through Celite, the product was extracted with ether and then concentrated to obtain compound 59 (yield: 15 %).


<Step 63>

[0125] Compound 59 (1.451 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (30 ml). TFA (0.7 ml) and  $\text{H}_2\text{O}$  (0.50 ml) were added to the obtained solution, and they were stirred at room temperature for 30 minutes and then concentrated.  $\text{CsCO}_3$  (9.6 mmol, 3.14 g) was added to the concentrate. The obtained mixture was dissolved in MeOH (22.5 ml) and  $\text{H}_2\text{O}$  (6 ml). After stirring for 17 hours, the product was acidified with HCl and then ion-exchanged to obtain SAIL-serine (60).

Synthesis of cysteine:

[0126] SAIL cysteine was synthesized according to scheme 12.

## Scheme 12



<Step 64>

20 **[0127]** Triphenylphosphine (2.46 mmol, 618 mg) was added to THF (6 ml), and the obtained mixture was cooled to 0°C in argon atmosphere. 40 % solution of DEAD in toluene (2.46 mmol, 1.12 ml) was added thereto. A solution of compound 59 (1.23 mmol, 356 mg) and thioacetic acid (2.46 mmol, 187 mg) in THF (3 ml) was added dropwise to the obtained mixture during 2 minutes. They were stirred at 0°C for 1 hour and then at room temperature for 1 hour. After the concentration followed by the treatment with the column, compound 7 was obtained. THF (5.0 ml) and 2 N NH<sub>4</sub>OH (5 ml) were added to compound 7 and they were stirred at room temperature for 30 minutes and then concentrated to obtain compound 8. After removing the protecting group, the product was treated with an ion exchange resin to obtain intended compound 61 in a yield of 27 %.

25

<Synthesis of asparagine>

30 **[0128]** SAIL aspartic acid was synthesized by using <sup>15</sup>N labeled ammonia gas as the nitrogen source by a method described in a literature (A. F. Beecham, J. Am. Chem. Soc., 76, 4615, 1953).

<Preparation of labeled protein>

35 **[0129]** As for the protein samples containing the above-described labeled amino acids, calmodulin protein was used as the model protein. Calmodulin was expressed by a method established by Zubay (Protein Expression, A Practical Approach, S. J. Higgins and B. D. Hames, pp. 201 to 223, Oxford University Press) selected from methods for cell-free protein synthesis. Differences between the method of the present invention and this known method are as follows: An E. coli extract was demineralized with PD-10 column (Amersham Biotech) and a mixture of the above-described amino acids in amounts proportional to the residue numbers was used (Fig. 11). pET-3a (Novagen) having calmodulin sequence inserted therein was used as the calmodulin expression DNA. After conducting the reaction in the cell-free synthetic system at 37°C for 8 hours, 4.4 mg of purified calmodulin was obtained from 44 mg of the amino acid mixture. SAIL calmodulin thus prepared had a deuteration rate of 56 %, and the number of signals in the side chains of amino acids was reduced to 60 % based on that observed when they were not labeled with deuterium.

40

45

<NMR determination of labeled protein>

50 **[0130]** For obtaining 1 mM of NMR sample from 4.4 mg of thus obtained SAIL calmodulin, this product was dissolved in a mixture of 100 mM KCl, 10 mM CaCl<sub>2</sub>, 0.1 mM NaN<sub>3</sub> and 10 % D<sub>2</sub>O, having pH 6.5. For the comparison with SAIL calmodulin, deuterium-free calmodulin was used. For the NMR determination in all the cases, Bruker DRX600 or DRX800 was used at 37°C. XWINNMR ver. 2.6 (Bruker) or NMRPipe ver. 1.7 (Delaglio et al., J. Biomol. NMR, 6,277-293, 1995) was used for NMR spectrum conversion. <sup>1</sup>H-<sup>13</sup>C CT-HSQC spectra of them are shown in Fig. 12. In the spectrum of SAIL calmodulin, the sharpness of the signals and reduction in degeneracy are recognized. According to the sharpening of the line width of the spectrum of SAIL calmodulin, the sensitivity in the determination was several times higher than that of the uniformly labeled calmodulin.

55

**[0131]** Further, the following determination was conducted for the purpose of assigning NMR signals due to the main chain and side chains of calmodulin:

## EP 1 457 482 B9

$^1\text{H}$ - $^{15}\text{N}$  HSQC, HNCA, HN(CO)CA, HNCO, HN(CA)CO, HNCACB, CBCA(CO)NH,  $^{15}\text{N}$ -TOCSY, HBHA(CO)NH, HCCH-COSY, HCCH-TOCSY, TOCSY (aromatic) and NOESY (aromatic).

[0132] In the determination of them, deuterium decoupling by continuous waves was employed for  $^1\text{H}$ - $^{13}\text{C}$  CT-HSQC, HNCACB, CBCA(CO)NH, HBHA(CO)NH, HCCH-COSY and HCCH-TOCSY.

[0133] The spectra obtained by this determination were analyzed according to Sparky ver. 3. 105 (UCSF) to assign the signals.

[0134] For detecting NOE for the stereostructure calculation,  $^{15}\text{N}$ -NOESY,  $^{13}\text{C}$ -NOESY and  $^1\text{H}$  NOESY were determined.

<Calculation of structure of labeled protein>

[0135] NOESY spectrum analysis and stereostructure calculation were conducted according to the assignment results of the main chain and side chain signals. In this method, a program CYANA (the Combined assignment and dynamics algorithm for NMR applications, c by Peter Guntert) (P. Guntert et al., J. Mol. Biol. 273, 283-298 (1997), T. Herrmann et al., J. Mol. Biol. 319, 209-227 (2002)) was used. This program was a combination of CANDID (NOESY automated analysis program) (Herrmann. T. et al., (2002). Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA, J. MOL. Biol. 319, 209-227) and DYANA (torsion angle dynamics algorithm for structure calculation) (P. Guntert et al., (1997), Torsion angle dynamics for NMR structure calculation with the new program DYANA. J. Mol. Biol. 273, 283-298.). CYANA was operated on Linux cluster loaded with 14 Xeon processor. One cycle starts with NOE analysis and ends with the determination of 20 stereostructures. The cycle was repeated seven times by the automatic repetition. Data used for the final structure calculation after completion of the 7 cycles are shown in the following table:

Chemical shift value	1201
Peak of $^{15}\text{N}$ -edited NOESY	1782
Peak of $^{13}\text{C}$ -edited NOESY	1853
Peak of 2D-NOESY	159

[0136] In the manual NOESY spectral analysis wherein the homogeneous, labeled sample was used, the calculation of the stereostructure took longer than several months. However, the structure can be determined in only 30 minutes by the above-described technique. This remarkable reduction in time is attained for the following reasons: Accurate signal analysis is made possible because signals unnecessary for the structure determination are removed and the sensitivity of the residual signals and the decomposition capacity are improved. Further, automated program is helpful. The final 20 structures thus obtained are shown in Fig. 13.

[0137] Namely, by the technique of the present invention, signals unnecessary for the structure determination are removed and the sensitivity of the residual signals is improved. Accordingly, it is made possible to rapidly and exactly analyze the signals of high-molecular protein and also to highly accurately determine the stereostructure thereof.

[0138] Thus, Examples 1 to 7 show the synthesis of amino acids having various isotope-labeled patterns and also the techniques of efficiently incorporating the labeled amino acids into a target protein by the cell-free protein preparation method without the metabolic transformation or dilution. Examples 1 to 7 also show the facts that precise structure information on high-molecular protein can be obtained by the determination of NMR spectrum of the obtained, labeled protein and that this information is far superior to that of conventional isotope NMR technique. In Example 7, RSD/SSD/SAD/PDM-amino acid-labeled protein was prepared by substituting all of 20 amino acid residues constituting protein with the labeled amino acids shown in Fig. 1 and this preparation was practically used for the stereo-structural determination. By the technique of the present invention in which the stereochemical assignment of residual protons is clear, it is made possible that the structure of the labeled protein solution can be rapidly and precisely determined. As shown in Fig. 10, by the technique described the stereochemical assignment of remaining protons is made clear by the calculation experiments with a computer. This fact indicates that by this technique, the highly accurate determination of the solution structure of the labeled protein (c) is possible and that the obtained results are in no way inferior to those obtained when the information of all proton is obtained (b).

[0139] As a matter of course, various modes are possible in the details of the present invention.

[0140] As described above in detail, by the first to the third modes of the present invention, the deuteration in the whole protein and the improvement in the sensitivity of the remaining signals are made possible. Thus, rapid, accurate signal analysis of high-molecular protein and highly precise stereostructure determination thereof are made possible

over the range of the conventional techniques.

**[0141]** Namely, the following effects are obtained by the present invention:

- (1) The line width of NMR signal is remarkably sharpened (improvement in the signal solving power).
- (2) The determination sensitivity is improved (shortening of the determination time)
- (3) The accuracy of NMR spectral analysis is improved, and shortening of the analysis time and automation of the analysis are made possible.
- (4) The scope of the molecular weight of protein to which NMR is applicable is widened (at least 2 times wider; the determination of the structure of protein having a molecular weight of about 50,000 is made possible).
- (5) The accuracy in the structure analysis is improved (because of the automatic stereospecific assignment of all the signals).
- (6) The structure determination and structure information are possible according to the signals of even the end of a side chain (possibility of the application of the technique to genome drug development and drug design).

**[0142]** As described above, the present invention and the technique of determining the structure clearly assumed as an extension of the invention are very effective in determining the structure with a high accuracy at a high throughput.

### Claims

1. A stable isotope-labeled amino acid which is at least one of amino acids constituting a protein and which has at least one of the following labelling patterns:

- (a) hydrogen atoms except at least one hydrogen atom in one or more methylene groups are deuterated,
  - (b) hydrogen atoms in one of prochiral gem-methyl groups are completely deuterated,
  - (c) hydrogen atoms in prochiral methyl groups are partially deuterated, and
  - (d) all hydrogen atoms except one of them in a methyl group are deuterated and hydrogen atoms in the aromatic ring are partially deuterated;
- and wherein all carbon atoms having remaining hydrogen atoms in the methylene group and/or methyl group are replaced with  $^{13}\text{C}$ ; and  
all nitrogen atoms are replaced with  $^{15}\text{N}$ .

2. A combination of stable isotope-labeled amino acids for constituting a target protein, wherein all the amino acids for constituting the target protein have the following label patterns:

- (a) when a methylene group having two hydrogen atoms is present, one of methylene hydrogen atoms is deuterated,
- (b) when prochiral gem-methyl groups are present, all hydrogen atoms in one methyl group are completely deuterated and hydrogen atoms in other methyl groups are partially deuterated,
- (d) when a methyl group other than those stated above is present, all hydrogen atoms except one of them in the methyl group are deuterated or all hydrogen atoms in the methyl group are deuterated,
- (e) when the aromatic ring has hydrogen atoms, the hydrogen atoms in the aromatic ring may be partially deuterated,
- (f) after the deuteration in above (a), (b) and (d), all carbon atoms of the hydrogen atom-containing methylene group and/or methyl group are replaced with  $^{13}\text{C}$ , and
- (g) all nitrogen atoms are replaced with  $^{15}\text{N}$ .

3. The combination of stable isotope-labeled amino acids of claim 2, wherein:

- (e) when the aromatic ring has hydrogen atoms, the hydrogen atoms in the aromatic ring are partially deuterated.

4. The combination of stable isotope-labeled amino acids of claim 3, wherein carbon atoms constituting carbonyl group and guanidyl group in the amino acids are replaced with  $^{13}\text{C}$ .

5. A method for producing a target protein composed of stable isotope-labeled amino acids, which comprises synthesizing the cell-free protein by using the combination of the stable isotope-labeled amino acids set forth in claim 2 as all the amino acids constituting the target protein.

6. The method for producing a target protein according to claim 5 wherein the combination of stable isotope-labeled amino acids of claim 3 is used as the all amino acids constituting the target protein.
7. The method for producing a target protein according to claim 5 wherein the combination of stable isotope-labeled amino acids of claim 4 is used as the all amino acids constituting the target protein.
8. A method for NMR analyzing the structure of a target protein, which comprises analyzing the structure of the target protein, in which all the amino acids constituting the target protein are replaced with the stable isotope-labeled amino acids of claim 2, by NMR spectral determination.
9. The method for NMR analyzing the structure of a target protein according to claim 8 wherein all the amino acids constituting the target protein are replaced with the stable isotope-labeled amino acids of claim 3.
10. The method for NMR analyzing the structure of a target protein according to claim 8 wherein all the amino acids constituting the target protein are replaced with the stable isotope-labeled amino acids of claim 4.

### Patentansprüche

1. Mit stabilen Isotopen markierte Aminosäure, die zumindest eine der Aminosäuren ist, die ein Protein bilden, und die mindestens eines der folgenden Markierungsmuster aufweist:
- (a) Wasserstoffatome mit Ausnahme mindestens eines Wasserstoffatoms in einer oder mehreren Methylgruppen werden deuteriert,
  - (b) Wasserstoffatome in einer der prochiralen geminalen Methylgruppen werden vollständig deuteriert,
  - (c) Wasserstoffatome in prochiralen Methylgruppen werden teilweise deuteriert, und
  - (d) alle Wasserstoffatome mit Ausnahme eines Wasserstoffatoms in einer Methylgruppe werden deuteriert, und Wasserstoffatome in dem aromatischen Ring werden teilweise deuteriert; und wobei alle Kohlenstoffatome mit verbleibenden Wasserstoffatomen in der Methylgruppe und/oder der Methylgruppe durch  $^{13}\text{C}$  ausgetauscht werden; und alle Stickstoffatome durch  $^{15}\text{N}$  ausgetauscht werden.
2. Kombination von mit stabilen Isotopen markierten Aminosäuren zur Bildung eines Zielproteins, wobei alle Aminosäuren zur Bildung des Zielproteins die folgenden Markierungsmuster aufweisen:
- (a) wenn eine Methylgruppe mit zwei Wasserstoffatomen anwesend ist, dann wird eines der Methylen-Wasserstoffatome deuteriert,
  - (b) wenn prochirale geminale Methylgruppen anwesend sind, dann werden alle Wasserstoffatome in einer Methylgruppe vollständig deuteriert, und Wasserstoffatome in anderen Methylgruppen werden teilweise deuteriert.
  - (d) wenn eine andere Methylgruppe als die oben angegebenen anwesend ist, werden alle Wasserstoffatome außer einem in der Methylgruppe deuteriert, oder alle Wasserstoffatome in der Methylgruppe werden deuteriert,
  - (e) wenn der aromatische Ring Wasserstoffatome aufweist, können die Wasserstoffatome in dem aromatischen Ring teilweise deuteriert werden,
  - (f) nach der Deuterierung in den obigen Abschnitten (a), (b) und (d) werden alle Kohlenstoffatome der wasserstoffatomhaltigen Methylgruppe und/oder Methylgruppe durch  $^{13}\text{C}$  ausgetauscht, und
  - (g) alle Stickstoffatome werden durch  $^{15}\text{N}$  ausgetauscht.
3. Kombination von mit stabilen Isotopen markierten Aminosäuren nach Anspruch 2, wobei:
- (e) wenn der aromatische Ring Wasserstoffatome aufweist, die Wasserstoffatome in dem aromatischen Ring teilweise deuteriert werden.
4. Kombination von mit stabilen Isotopen markierten Aminosäuren nach Anspruch 3, wobei Kohlenstoffatome, die in den Aminosäuren eine Carbonylgruppe und eine Guanidylgruppe bilden, durch  $^{13}\text{C}$  ausgetauscht werden.
5. Verfahren zur Erzeugung eines Zielproteins, das aus mit stabilen Isotopen markierten Aminosäuren besteht, wobei das Verfahren die Synthetisierung des zellfreien Proteins unter Verwendung der Kombination der in Anspruch 2

dargestellten, mit stabilen Isotopen markierten Aminosäuren als alle das Zielprotein bildenden Aminosäuren aufweist.

- 5 6. Verfahren zur Erzeugung eines Zielproteins nach Anspruch 5, wobei die Kombination von mit stabilen Isotopen markierten Aminosäuren nach Anspruch 3 als alle das Zielprotein bildenden Aminosäuren verwendet wird.
7. Verfahren zur Erzeugung eines Zielproteins nach Anspruch 5, wobei die Kombination von mit stabilen Isotopen markierten Aminosäuren nach Anspruch 4 als alle das Zielprotein bildenden Aminosäuren verwendet wird.
- 10 8. NMR-Verfahren zur Strukturanalyse eines Zielproteins, das eine Strukturanalyse des Zielproteins aufweist, wobei alle Aminosäuren, die das Zielprotein bilden, durch die mit stabilen Isotopen markierten Aminosäuren nach Anspruch 2 ausgetauscht sind, durch Bestimmung des NMR-Spektrums.
- 15 9. NMR-Verfahren zur Strukturanalyse eines Zielproteins nach Anspruch 8, wobei alle Aminosäuren, die das Zielprotein bilden, durch die mit stabilen Isotopen markierten Aminosäuren nach Anspruch 3 ausgetauscht sind.
10. NMR-Verfahren zur Strukturanalyse eines Zielproteins nach Anspruch 8, wobei alle Aminosäuren, die das Zielprotein bilden, durch die mit stabilen Isotopen markierten Aminosäuren nach Anspruch 4 ausgetauscht sind.

20

### Revendications


- 25 1. Acide aminé marqué par un isotope stable qui est au moins l'un des acides aminés constituant une protéine et qui possède au moins un des modèles de marquage qui suivent:
- 30 (a) les atomes d'hydrogène excepté au moins un atome d'hydrogène dans un ou plusieurs groupes méthylènes sont deutérés,  
 (b) les atomes d'hydrogène dans un des groupes gem-méthyles prochiraux sont complètement deutérés,  
 (c) les atomes d'hydrogène dans les groupes méthyles prochiraux sont partiellement deutérés, et  
 (d) tous les atomes d'hydrogène excepté l'un d'entre eux dans un groupe méthyle sont deutérés et les atomes d'hydrogène dans le cycle aromatique sont partiellement deutérés;  
 et dans lequel tous les atomes de carbone ayant des atomes d'hydrogène restants dans le groupe méthylène et/ou le groupe méthyle sont remplacés par des  $^{13}\text{C}$ ; et  
 tous les atomes d'azote sont remplacés par  $^{15}\text{N}$ .
- 35 2. Combinaison d'acides aminés marqués par un isotope stable pour constituer une protéine cible, dans laquelle tous les acides aminés pour constituer la protéine cible possèdent les modèles de marquage qui suivent:
- 40 (a) lorsqu'un groupe méthylène possédant deux atomes d'hydrogène est présent, l'un des atomes d'hydrogène du méthylène est deutéré,  
 (b) lorsque des groupes gem-méthyles prochiraux sont présents, tous les atomes d'hydrogène dans un groupe méthyle sont complètement deutérés et les atomes d'hydrogène dans les autres groupes méthyles sont partiellement deutérés,  
 (d) lorsqu'un groupe méthyle autre que ceux énoncés ci-dessus est présent, tous les atomes d'hydrogène excepté l'un d'entre eux dans le groupe méthyle sont deutérés ou tous les atomes d'hydrogène dans le groupe méthyle sont deutérés,  
 (e) lorsque le cycle aromatique possède des atomes d'hydrogène, les atomes d'hydrogène dans le cycle aromatique peuvent être partiellement deutérés,  
 (f) après la deutération dans (a), (b) et (d) ci-dessus, tous les atomes de carbone du groupe méthylène et/ou  
 50 du groupe méthyle contenant des atomes d'hydrogène sont remplacés par des  $^{13}\text{C}$ , et  
 (g) tous les atomes d'azote sont remplacés par  $^{15}\text{N}$ .
- 55 3. Combinaison d'acides aminés marqués par un isotope stable selon la revendication 2, dans laquelle:
- (e) lorsque le cycle aromatique possède des atomes d'hydrogène, les atomes d'hydrogène dans le cycle aromatique sont partiellement deutérés.
4. Combinaison d'acides aminés marqués par un isotope stable selon la revendication 3, dans laquelle les atomes de

## EP 1 457 482 B9

carbone constituant un groupe carbonyle et un groupe guanidyle dans les acides aminés sont remplacés par des  $^{13}\text{C}$ .


- 5
5. Procédé pour la production d'une protéine cible composée d'acides aminés marqués par un isotope stable, qui comprend la synthèse de la protéine sans cellule en utilisant la combinaison d'acides aminés marqués par un isotope stable présentée dans la revendication 2 en tant que la totalité des acides aminés constituant la protéine cible.
- 10
6. Procédé pour la production d'une protéine cible selon la revendication 5, dans lequel la combinaison d'acides aminés marqués par un isotope stable selon la revendication 3 est utilisée en tant que la totalité des acides aminés constituant la protéine cible.
- 15
7. Procédé pour la production d'une protéine cible selon la revendication 5, dans lequel la combinaison d'acides aminés marqués par un isotope stable selon la revendication 4 est utilisée en tant que la totalité des acides aminés constituant la protéine cible.
- 20
8. Procédé pour une analyse RMN de la structure d'une protéine cible, qui comprend l'analyse de la structure de la protéine cible, dans lequel tous les acides aminés constituant la protéine cible sont remplacés par les acides aminés marqués par un isotope stable selon la revendication 2, par une détermination spectrale RMN.
- 25
9. Procédé pour une analyse RMN de la structure d'une protéine cible selon la revendication 8, dans lequel tous les acides aminés constituant la protéine cible sont remplacés par les acides aminés marqués par un isotope stable selon la revendication 3.
- 30
10. Procédé pour une analyse RMN de la structure d'une protéine cible selon la revendication 8, dans lequel tous les acides aminés constituant la protéine cible sont remplacés par les acides aminés marqués par un isotope stable selon la revendication 4.
- 35
- 40
- 45
- 50
- 55

Fig. 1




Figs. 2

$^1\text{H}$ - $^{13}\text{C}$  HSQC spectrum of EPPlb protein (18.2 kDa) containing SAD-glycine incorporated thereinto



Figs. 3

HCCT TOCSY spectrum of EPP1b protein (18.2 kDa) containing SAD-lysine incorporated thereinto




(a) EPP1b protein containing SAD-lysine (18) incorporated thereinto

(b) EPP1b protein containing  $[\text{ul-}^{13}\text{C}_2; ^{15}\text{N}]$  lysine incorporated thereinto

Figs. 4

HCCT TOCSY spectrum of EPPlb protein (18.2 kDa) containing SAD-glutamine incorporated thereinto




(a) EPPlb protein containing SAD-glutamine (18) incorporated thereinto

(b) EPPlb protein containing [ $^{13}\text{C}_2$ ;  $^{15}\text{N}$ ] glutamine incorporated thereinto

Figs. 5

$^1\text{H}$ - $^{13}\text{C}$  HSQC spectrum of EPPlb protein (18.2 kDa) containing SAD/PDM-leucine incorporated therein in  $^1\text{H}$ - $^{13}\text{C}$   $\beta$  region




(a) EPPlb protein containing SAD/PDM-leucine (33) incorporated therein

(b) EPPlb protein containing  $[\text{ul-}^{13}\text{C}; ^{15}\text{N}]$ -leucine incorporated therein

Figs. 6

$^1\text{H}$ - $^{13}\text{C}$  HSQC spectrum of EPPlb protein (18.2 kDa) containing SAD/PDM-leucine incorporated therein in  $^1\text{H}$ - $^{13}\text{C}$   $\gamma$  region




(a) EPPlb protein containing SAD/PDM-leucine (33) incorporated therein

(b) EPPlb protein containing  $[\text{ul-}^{13}\text{C}; ^{15}\text{N}]$ -leucine incorporated therein

Figs. 7

$^1\text{H}$ - $^{13}\text{C}$  HSQC spectrum of EPPlb protein (18.2 kDa) containing SAD/PDM-methionine incorporated thereinto in  $^1\text{H}$ - $^{13}\text{C}$   $\gamma$  region




(a) EPPlb protein containing SAD/PDM-methionine (41) incorporated thereinto

(b) EPPlb protein containing  $[\text{ul-}^{13}\text{C}; ^{15}\text{N}]$ -methionine incorporated thereinto

Fig. 9


Slice data of H 92 signals



- (a) Uniform  $^{13}\text{C}$ ,  $^{15}\text{N}$  label by an ordinary method
- (b) Amino acid selective label by an ordinary method
- (c) Histidine residue in which pro-S proton is deuterated
- (d) Histidine residue in which pro-R proton is deuterated

Fig. 10

Simulation of the calculation of structure of lysozyme



(a) Structure obtained by the X-ray analysis of crystal structure

(b) NOE information of all protons

Structure obtained by the main chain dihedral angle information by TALOS and NH-dipole

(c) NOE information of remaining protons after SAD/PDM labeling


Structure obtained by the main chain dihedral\_angle information by TALOS and NH-dipole

(d) NOE (CH3, ring, & HN) of only CH3, ring & HN

Structure obtained by the main chain dihedral angle information by TALOS and NH-dipole

Fig. 11

# SAIL Calmodulin Preparation



43.2 mg → 4.4 mg calmodulin

Fig. 12

# → Calmodulin

$^1\text{H}$ - $^{13}\text{C}$  CT HSQC

*Conventional Approach*

*Our Approach*






Fig. 13



## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 9911589 A [0004]

## Non-patent literature cited in the description

- Shin Seikagaku Jikken Koza. Tokyo Kagaku Dojin, 15 November 1990 [0005]
- **K. P. R. Kartha et al.** *Tetrahedron Lett.*, 1986, vol. 27, 3415 [0036]
- **Nicolaou et al.** *J. Am. Chem. Soc.*, 1988, vol. 110, 4673 [0037]
- **C. Hubschwerlen et al.** *Synthesis*, 1986, 962 [0037]
- **Joseph A. Tino et al.** *J. Med. Chem.*, 1993, vol. 36, 1221 [0039]
- **E. Kariya et al.** *J. Biomol. NMR*, 2000, vol. 18, 75-76 [0048] [0056] [0057] [0063] [0081] [0082] [0092] [0093] [0098]
- **M. Oba et al.** *J. Org. Chem.*, 1999, vol. 64, 9275 [0052]
- **E. Kariya et al.** *Biomol. NMR*, 2000, vol. 18, 75-76 [0062]
- **K. Ramalingam et al.** *J. Org. Chem.*, 1988, vol. 53, 1900-1903 [0086]
- **Makoto Oba et al.** *J. Chem. Soc., Perkin Trans. 1*, 1995, 1603 [0096]
- **E. Karia et al.** *J. Biomol. NMR*, 2000, vol. 18, 75-76 [0097]
- **Jack E. Baldwin et al.** *Tetrahedron*, 1995, vol. 51, 4089-4100 [0104]
- **M. Oba et al.** *J. Org. Chem.*, 1999, vol. 64, 9275-9278 [0105]
- **T. Shiraiwa et al.** *Bull. Chem. Soc. Jpn.*, 1991, vol. 64, 191-195 [0110]
- **Ernesto Nicols.** *J. Org. Chem.*, 1993, vol. 58, 766-770 [0110]
- **V. Schurig et al.** *J. Org. Chem.*, 1980, vol. 45, 538-541 [0112]
- **Richard K. Hill et al.** *J. Am. Chem. Soc.*, 1980, vol. 102, 7344-7348 [0113]
- **Nicholas M. Kelly et al.** *Tetrahedron Lett.*, 1996, vol. 37, 1517-1520 [0114]
- **Y. Ueno et al.** *Chem. Lett.*, 1983, 795 [0116]
- **Frieder W. Lichtenthaler et al.** *Synthesis*, 1988, 790 [0121]
- **Mark A. Blaskovich et al.** *J. Org. Chem.*, 1998, vol. 63, 3631-3646 [0123]
- **A. F. Beecham.** *J. Am. Chem. Soc.*, 1953, vol. 76, 4615 [0128]
- **Zubay ; S. J. Higgins ; B. D. Hames.** Protein Expression, A Practical Approach. Oxford University Press, 201-223 [0129]
- **Delaglio et al.** *J. Biomol. NMR*, 1995, vol. 6, 277-293 [0130]
- **P. Guntert et al.** *J. Mol. Biol.*, 1997, vol. 273, 283-298 [0135]
- **T. Herrmann et al.** *J. Mol. Biol.*, 2002, vol. 319, 209-227 [0135]
- **Herrmann. T. et al.** Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. *J. MOL. Biol.*, 2002, vol. 319, 209-227 [0135]
- **P. Guntert et al.** Torsion angle dynamics for NMR structure calculation with the new program DYANA. *J. Mol. Biol.*, 1997, vol. 273, 283-298 [0135]